Call for improvements in EU regulatory environment for generics and biosimilars from EGA

26 January 2011

“The EU regulatory environment needs to be optimized in order to deal with the growing demand for generic and biosimilar medicines. These medicines, which are now front-line treatments for a whole range of chronic diseases and account for nearly 50% of all medicines dispensed to European patients are the key to healthcare sustainability in the EU and the European regulatory system needs to reflect this reality.”

This was the key message of Greg Perry, director general of the European Generic medicines Association (EGA), as he presented the association’s Vision 2015 at the EGA’s 10th Regulatory and Scientific Affairs Conference, held in London, UK, yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology